I have to agree it has been but it’s also been a great learning experience for bio investing in future and timing for entries and exits - just need to watch out for company pivots and strategy changes (jest) I’ve personally felt the opportunity cost this past year and a bit however if the company is able to generate proof of concept this year, that opportunity cost sting should fade pretty quick. Onwards for ethics approval and ultimately first dosing.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
-0.050(3.75%) |
Mkt cap ! $223.2M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $125.2K | 96.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21173 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 6431 | 2 |
View Market Depth
| Last trade - 15.34pm 23/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |